World Without Multiple Myeloma Leader
Janssen R&D US
Why I'm a JPAL
To engage with the most innovative science anywhere to eradicate multiple myeloma and AL amyloidosis
Brendan Weiss, M.D., is Senior Director, Multiple Myeloma Strategy Leader within the Hematologic Malignancies Disease Area Stronghold at Janssen Research and Development. In this role he will lead Janssen’s efforts in developing the right strategies, advancing sciences and developing transformational medicines aimed at preventing, intercepting and curing plasma cell diseases, specifically multiple myeloma and AL amyloidosis. Prior to joining Janssen in October 2017, he was an Assistant Professor of Medicine in the Section of Hematologic Malignancies and Bone Marrow Transplantation within the Division of Hematology-Oncology at the Abramson Cancer Center of the University of Pennsylvania. At Penn, he specialized in the treatment and research of multiple myeloma, AL amyloidosis and Waldenström’s macrogobulinemia. He was the Founder and Director of the Penn Amyloidosis Program, a comprehensive, multidisciplinary program for the evaluation, treatment and research of patients with amyloidosis. He has been an investigator on multiple clinical trials of immunotherapies (monoclonal antibodies and chimeric antigen receptor T-cells (CAR-T)) for multiple myeloma and AL amyloidosis.
Less, but better.
I was a physician in the US Army until 2011 and deployed to Iraq twice during my service.